Herpesvirus Reactivations in Critically-Ill COVID-19 Patients with Autoantibodies Neutralizing Type I Interferons
View ORCID ProfileIdoia Busnadiego, View ORCID ProfileIrene A. Abela, View ORCID ProfilePascal M. Frey, Daniel A. Hofmaenner, Thomas C. Scheier, View ORCID ProfileReto A. Schuepbach, Philipp K. Buehler, Silvio D. Brugger, View ORCID ProfileBenjamin G. Hale
doi: https://doi.org/10.1101/2022.03.19.22272532
Idoia Busnadiego
aInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland
Irene A. Abela
bDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
bDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
Pascal M. Frey
bDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
cDepartment of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
Daniel A. Hofmaenner
dInstitute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
Thomas C. Scheier
bDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
Reto A. Schuepbach
dInstitute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
Philipp K. Buehler
dInstitute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
Silvio D. Brugger
bDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
Benjamin G. Hale
aInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
- Supplemental Figure 1[supplements/272532_file05.tif]
- Supplemental Figure 2[supplements/272532_file06.tif]
Posted March 21, 2022.
Herpesvirus Reactivations in Critically-Ill COVID-19 Patients with Autoantibodies Neutralizing Type I Interferons
Idoia Busnadiego, Irene A. Abela, Pascal M. Frey, Daniel A. Hofmaenner, Thomas C. Scheier, Reto A. Schuepbach, Philipp K. Buehler, Silvio D. Brugger, Benjamin G. Hale
medRxiv 2022.03.19.22272532; doi: https://doi.org/10.1101/2022.03.19.22272532
Herpesvirus Reactivations in Critically-Ill COVID-19 Patients with Autoantibodies Neutralizing Type I Interferons
Idoia Busnadiego, Irene A. Abela, Pascal M. Frey, Daniel A. Hofmaenner, Thomas C. Scheier, Reto A. Schuepbach, Philipp K. Buehler, Silvio D. Brugger, Benjamin G. Hale
medRxiv 2022.03.19.22272532; doi: https://doi.org/10.1101/2022.03.19.22272532
Subject Area
Subject Areas
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2599)
- Dermatology (218)
- Emergency Medicine (391)
- Epidemiology (12134)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4028)
- Geriatric Medicine (379)
- Health Economics (670)
- Health Informatics (2605)
- Health Policy (994)
- Hematology (358)
- HIV/AIDS (831)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3797)
- Nursing (208)
- Nutrition (563)
- Oncology (1989)
- Ophthalmology (576)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (249)
- Palliative Medicine (72)
- Pathology (470)
- Pediatrics (1098)
- Primary Care Research (443)
- Public and Global Health (6469)
- Radiology and Imaging (1379)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (337)
- Surgery (438)
- Toxicology (51)
- Transplantation (185)
- Urology (165)